Department of Cardiovascular Surgery, The Affiliated Hospital, Southwest Medical University, Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Key Laboratory of cardiovascular remodeling and dysfunction, Luzhou, Sichuan, 646000, China.
Nanjing Medical University, Nanjing, 211166, P. R. China.
Adv Healthc Mater. 2024 Jun;13(16):e2304432. doi: 10.1002/adhm.202304432. Epub 2024 Mar 17.
Vascular diseases are the leading cause of ischemic necrosis in tissues and organs, necessitating using vascular grafts to restore blood supply. Currently, small vessels for coronary artery bypass grafts are unavailable in clinical settings. Decellularized small-diameter tissue-engineered vessel grafts (SD-TEVGs) hold significant potential. However, they face challenges, as simple implantation of decellularized SD-TEVGs in animals leads to thrombosis and calcification due to incomplete endothelialization. Consequently, research and development focus has shifted toward enhancing the endothelialization process of decellularized SD-TEVGs. This paper reviews preclinical studies involving decellularized SD-TEVGs, highlighting different strategies and their advantages and disadvantages for achieving rapid endothelialization of these vascular grafts. Methods are analyzed to improve the process while addressing potential shortcomings. This paper aims to contribute to the future commercial viability of decellularized SD-TEVGs.
血管疾病是导致组织和器官缺血性坏死的主要原因,需要使用血管移植物来恢复血液供应。目前,临床应用中还没有用于冠状动脉旁路移植术的小血管。脱细胞小直径组织工程血管移植物(SD-TEVGs)具有很大的潜力。然而,它们面临着挑战,因为简单地将脱细胞的 SD-TEVGs 植入动物体内会导致不完全内皮化的血栓形成和钙化。因此,研究和开发的重点已经转向增强脱细胞 SD-TEVGs 的内皮化过程。本文回顾了涉及脱细胞 SD-TEVGs 的临床前研究,强调了不同策略及其优缺点,以实现这些血管移植物的快速内皮化。分析了改进该过程的方法,同时解决了潜在的缺点。本文旨在为脱细胞 SD-TEVGs 的未来商业可行性做出贡献。